Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+18.25%
|
-
|
|
Jan 06
2023
|
John Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,900
+50.0%
|
-
|
|
Dec 05
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
20,000
-9.84%
|
$1,000,000
$50.09 P/Share
|
|
Dec 05
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.8%
|
$160,000
$8.44 P/Share
|
|
Nov 03
2022
|
Kate Haviland Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,100
+1.18%
|
$47,300
$43.98 P/Share
|
|
Nov 03
2022
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
533
-1.21%
|
$23,985
$45.24 P/Share
|
|
Oct 04
2022
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
3,477
-6.18%
|
$232,959
$67.3 P/Share
|
|
Aug 24
2022
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.91%
|
$375,000
$75.11 P/Share
|
|
Aug 24
2022
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.84%
|
$75,000
$15.01 P/Share
|
|
Aug 22
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
8,410
-2.2%
|
$588,700
$70.89 P/Share
|
|
Aug 22
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,410
+4.2%
|
$126,150
$15.01 P/Share
|
|
Aug 19
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
1,590
-0.86%
|
$111,300
$70.02 P/Share
|
|
Aug 19
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,590
+0.85%
|
$23,850
$15.01 P/Share
|
|
Aug 16
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
20,000
-3.36%
|
$1,360,000
$68.72 P/Share
|
|
Aug 16
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.8%
|
$160,000
$8.44 P/Share
|
|
Aug 08
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.17%
|
$700,000
$70.07 P/Share
|
|
Aug 08
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.54%
|
$50,000
$5.34 P/Share
|
|
Aug 05
2022
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
2,500
-11.73%
|
$162,500
$65.0 P/Share
|
|
Aug 04
2022
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
2,500
-10.5%
|
$150,000
$60.44 P/Share
|
|
Jun 23
2022
|
Habib J Dable Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,900
+50.0%
|
-
|
|
Jun 21
2022
|
Lynn Seely Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+23.61%
|
-
|
|
Jun 21
2022
|
George Demetri |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+23.61%
|
-
|
|
Jun 21
2022
|
Alexis Borisy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+3.62%
|
-
|
|
Jun 21
2022
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+16.24%
|
-
|
|
Jun 21
2022
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+4.66%
|
-
|
|
Jun 21
2022
|
Lonnel Coats Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+23.61%
|
-
|
|
Jun 21
2022
|
Daniella Beckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+30.23%
|
-
|
|
Jun 07
2022
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,155
-10.36%
|
$189,300
$60.0 P/Share
|
|
Jun 06
2022
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,220
-3.85%
|
$71,980
$59.76 P/Share
|
|
Jun 06
2022
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,908
-6.24%
|
$112,572
$59.76 P/Share
|
|
May 23
2022
|
Nicholas Lydon |
BUY
Exercise of conversion of derivative security
|
Direct |
10,909
+17.74%
|
$207,271
$19.53 P/Share
|
|
May 16
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
20,000
-3.37%
|
$1,100,000
$55.44 P/Share
|
|
May 16
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.8%
|
$160,000
$8.44 P/Share
|
|
Apr 06
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.66%
|
$350,000
$70.11 P/Share
|
|
Apr 06
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.59%
|
$75,000
$15.01 P/Share
|
|
Mar 17
2022
|
George Demetri |
SELL
Open market or private sale
|
Direct |
10
-0.17%
|
$580
$58.56 P/Share
|
|
Mar 16
2022
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,219
-6.55%
|
$133,140
$60.0 P/Share
|
|
Mar 10
2022
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,339
-19.57%
|
$133,323
$57.15 P/Share
|
|
Mar 07
2022
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,047
-3.0%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
1,047
-1.83%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,047
-2.5%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,048
-1.14%
|
$58,688
$56.18 P/Share
|
|
Mar 07
2022
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,047
-2.61%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,047
-2.36%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
502
-2.06%
|
$28,112
$56.19 P/Share
|
|
Mar 07
2022
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,047
-2.3%
|
$58,632
$56.19 P/Share
|
|
Mar 07
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
4,843
-2.57%
|
$271,208
$56.19 P/Share
|
|
Mar 07
2022
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
256
-2.1%
|
$14,336
$56.19 P/Share
|
|
Mar 04
2022
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
20,000
-2.48%
|
$1,140,000
$58.0 P/Share
|
|
Mar 04
2022
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.68%
|
$160,000
$8.44 P/Share
|